INTRODUCTION
Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina characterized by loss of central vision in old age. In particular, wet-type or exudative AMD, which is characterized by choroidal neovascularization, may cause severe loss of vision in these patients.
AMD is the leading cause of central blindness among patients aged over 65 years in developed countries. The prevalence of AMD among individuals aged between 65 and 75 years is 10% and it is 25% among those aged 75 years and over. Patients with AMD may face difficulties in relation to many of the basic activities of daily living, such as writing, housework, self-care, driving and shopping. They may also suffer emotional distress and depression, and have a reduced quality of life (QoL). 1 Furthermore, loss of vision increases the risk of falling and fall-related injuries. 2 In all of its aspects, AMD is recognized as an important public health problem.
Although the effects of exudative AMD (e-AMD) on quality of life, depression and physical and mental health have been studied more extensively in well-developed countries, data is relatively lacking from developing or underdeveloped countries. Moreover, differences in its effects may be seen between communities. Different social traits, belief sets and cultural characteristics in different communities may lead patients to be influenced psychologically in different manners from the same disease.
The hospital anxiety and depression scale (HADS) was designed to measure the risks of anxiety and depression and their levels. The test includes two subscales: HADS-A, which assesses anxiety, and HADS-D, which assesses depression, both including seven items. 
OBJECTIVE
In the current study, we aimed to evaluate the impact of e-AMD on the QoL of patients, using the HADS-A, HADS-D, NEI-VFQ-25 and SF-36 questionnaires. The patients with severe AMD were aged over 50 years, had exudative-type AMD and were already receiving anti-vascular endothelial growth factor (anti-VEGF) treatment on an as-needed basis to treat e-AMD. All of the patients in the study group had e-AMD in at least one eye, with Snellen visual acuity of 0.5 or less.
METHODS

This study was undertaken between
Exudative AMD was defined and diagnosed as occurrences of intraretinal and subretinal fluid caused by choroidal neovascularization.
It was accompanied by drusen and retinal pigment epithelial detachments, which were demonstrated by means of fundus fluorescein angiography and spectral domain optical coherence tomography (Heidelberg Spectralis OCT and HRA, Heidelberg, Germany).
Patients with comorbid disorders were excluded from the study.
In addition, patients with glaucoma, optic neuropathy, diabetic retinopathy, uveitis, amblyopia, degenerative myopia or cataracts were also excluded. 
RESULTS
A total of 200 patients and 120 controls were enrolled in the study.
The mean ages in the e-AMD and control groups were 68.40 ± 9.8 and 66.31 ± 8.98 years, respectively (P = 0.06). The mean binocular visual acuity (according to a Snellen chart line) was 0.52 ± 0.31 in the e-AMD group and 0.96 ± 0.04 in the control group (P = 0.00). The visual acuity among patients in the e-AMD group was 0.37 ± 0.31 in the right eye and 0.39 ± 0.32 in the left eye (P = 0.80). There was no significant difference regarding smoking, education, sex or income levels between the control and patient groups ( Table 1) .
The patients in the e-AMD group performed significantly worse than the controls in all of the items of the NEI-VFQ-25 test (general health, general vision, vision-specific mental health, vision-specific social functioning, vision-specific dependency, ocular pain, near and distant activities, driving, color vision and peripheral vision) (P < 0.05 for all items). We were unable to compare driving performance. The driving test was not applicable to the patients with e-AMD, because many of them were not drivers even before the onset of the disease. The NEI-VFQ-25 scores for general vision, near vision, peripheral vision, color vision, dependency and ocular pain were significantly lower among the patients with bilateral e-AMD than among those who had unilateral disease ( Table 2) . Table 3 .
HADS-A and HADS-D scores were compared with visual acuity, laterality of disease and demographic characteristics among the patients with exudative AMD. This is shown in Table 4 .
The patients with e-AMD had significantly lower mean scores than those of the controls for each of the items of the SF-36 QoL scale (P < 0.001). The test scores showed decreases with increasing age in both of the groups. The test scores declined with reduced vision, particularly in the domains of physical functioning and vitality, among the patients with e-AMD. The test scores also declined with extended disease duration (P < 0.001). The physical functioning and vitality scores were significantly higher among females than among males (P < 0.001) in the e-AMD group, but not in the control group. The data from the SF-36 scale in bilateral and unilateral e-AMD cases and in the control group are shown in Table 5 .
DISCUSSION
The results from our study showed that patients with e-AMD were more likely to experience depression and anxiety symptoms 
Subscales of SF-36
Physical functioning P = 0.061; r = -0.13 P < 0.001; r = 0.25 P < 0.001; r = -0.36
Role limitation due to physical health P = 0.067; r = -0.13 P < 0.001; r = 0.29 P < 0.001; r = -0.24
Role limitation due to emotional problems P = 0.005; r = -0.20 P < 0.001; r = 0.27 P < 0.001; r = -0.22
Energy/fatigue P = 0.231; r = -0.08 P < 0.001; r = 0. Previous studies have shown that there is a significant association between chronic eye diseases and depression.
Depression may develop either as a result of a chronic physical disorder or due to a limitation on daily activities following vision impairment. 8 Watson et al. reported that anxiety often accompanies depression, 9 and Mathew et al. found that 44% of the patients with AMD and 18% of the controls had depressive symptoms. 10 Although reduced visual acuity is used as the primary outcome measurement in the majority of trials, loss of contrast sensitivity and color vision and increased susceptibility to glare from light are also associated with decreased vision-specific QoL among patients with AMD.
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A series of cohort studies conducted by Casten et al. showed that the prevalence of depression among patients with AMD was between 20% and 43%. 12, 13 Several researchers have assessed the relationship between severity of AMD and depressive symptoms. 14, 15 One of these studies suggested that there was no relationship between AMD and anxiety. 15 A cross-sectional study found that the rate of depressive symptoms was not significantly different between patients with early AMD and those with late AMD (15.7% versus 17.2%). 16 However, some other studies reported that the rate of depressive symptoms increased with the severity of e-AMD. 17 In a cross-sectional study, the proportion of patients with e-AMD who presented depression was 17.9%. 27 In case-control studies, the percentage of depression is usually found to be significantly higher among patients with e-AMD. 17, 18 Popescu et al.
examined whether the percentage of depression among patients with AMD, glaucoma and Fuchs corneal dystrophy was higher than among controls and found that while it was 8% among the controls, it was 29% among patients with glaucoma and 39% among patients with AMD. 19 In a controlled study conducted on patients with glaucoma and AMD, Kocak et al. showed that the percentage of depression was significantly higher among the patients with glaucoma or AMD than among the controls. 20 However, the difference between the patients with glaucoma and those with AMD was not significant.
With regard to the relationship between AMD and anxiety, while several case-control studies failed to show any significant relationship, 18 several others showed higher rates of anxiety among patients with AMD. 17 Some studies did not find any relationship between the severity of AMD and anxiety symptoms. 17, 18 In the current study, we found significant differences in both the HADS-A and the HADS-D score between the patients with e-AMD and the controls.
The NEI-VFQ-25 test is among the most commonly used vision-specific QoL scales. Orr et al. found that NEI-VFQ-25
scores were positively correlated with good vision. 21 In the AgeRelated Eye Disease Study, the researchers assessed NEI-VFQ-25
scores twice, with a four-year interval between assessments, and demonstrated that there was a significant association between NEI-VFQ-25 scores and the progression of AMD and vision loss.
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A clinical study conducted on patients with e-AMD who received pegaptanib, ranibizumab or aflibercept showed that these treatments improved their QoL and reduced their dependence in relation to daily activities. In addition, it showed that these treatments decreased the incidences of depression and fall-related injuries. 23 In the EQUADE study, using the NEI-VFQ-25 test, the researchers demonstrated that poor QoL was associated with impaired visual functions, prolonged duration of illness and poor social support (paid caregivers and home healthcare services). 24 In a study conducted on patients with e-AMD who received photodynamic treatment, their QoL was assessed using pre and post-treatment NEI-VFQ-25 test scores. Although visual acuity was maintained in 71% of the patients, photodynamic treatment failed to improve their QoL. In the current study, we found a significant correlation between improved visual acuity and increased NEI-VFQ-25 test scores. Poor visual acuity and prolonged treatment duration were associated with lower test scores and poorer QoL.
The SF-36 test is a practical instrument for assessing QoL among older adults. This test has, particularly, been used among patients with glaucoma. In a study performed in Turkey, using the SF-36 scale, it was shown that QoL was lower among patients with glaucoma. 25 In another study, physical functioning, role-physical, bodily pain, social functioning and mental health scores were found to be significantly lower among the patients with glaucoma than among the controls. 26 In a study in which the participants were divided into three groups, comprising patients with glaucoma, patients with a suspicion of glaucoma and controls, the patients with glaucoma had the lowest SF-36 scores and those with a suspicion of glaucoma had the second lowest scores. 27 In the current study, the patients with e-AMD tended to score lower than the controls across all of the QoL domains. The test scores particularly showed that there were declines in the domains of physical functioning and vitality with increasing disease duration and reduced visual acuity.
Exudative AMD is a chronic disease that gradually causes significant central visual loss. Geographical, population and sociodemographic differences may lead to variable results regarding the scores on depression, anxiety and quality-of-life scales. These results can also be influenced by factors relating to patients' expectations.
Patients' beliefs and fears relating to the disease and the ways in which they react to the disease need to be assessed. Compliance with treatment, in relation to chronic diseases, affects the course of the disease and the success of the treatment.
It should be borne in mind that psychiatric support may be needed in order to provide optimal compliance with treatment, in relation to mental health status and quality of life among e-AMD patients. The HADS-A, HADS-D, SF-36 and NEI-VFQ-25 scales can be used to fully ascertain the physical and mental health status of patients with e-AMD. Our study showed how our patient population with e-AMD was affected overall through undergoing treatment for chronic anti-VEGF treatment.
Compared with previous studies, the differences in the geographical, educational and sociodemographic characteristics of the participants in this study may, in part, account for the differences in the anxiety and depression rates and in the vision-specific QoL scores. Overall, we found that patients with e-AMD were especially at risk of impaired QoL. Therefore, these patients require close follow-up.
The limitations of this study include the small size of the sample that was used to investigate the outcome variables. The small population size may have limited the power of the study for making statistical differentiation to ascertain any slight significances in the subgroup analyses. In addition, the possible influence of the number of intravitreal anti-VEGF treatments for e-AMD on the quality-of-life scales was not evaluated. It would be valuable to study the different stages of the course of anti-VEGF treatment for e-AMD, such as the initial, midterm or long-term stage.
On the other hand, the use of three different scales to assess possible impairment of quality of life and emotional mood in the same population suffering from e-AMD was the strength of our study. Moreover, all the scales had also been validated in our country.
CONCLUSION
Our results showed that patients with e-AMD had higher levels of symptoms of depression and anxiety and lower QoL, in comparison with the controls. The quality of life of these patients with e-AMD decreased as the disease duration increased and their visual acuity decreased. Our study indicated that treatments for patients with e-AMD should be managed in terms of dealing with their overall health. Further multicenter studies with large sample sizes are required to provide better validated data.
